UNSPSC 51201648: Rubella and mumps virus vaccine

This classification denotes a combination vaccine. The first component of this combination vaccine addresses that acute infectious disease caused by the rubella virus, of type species of rubivirus causing acute infection in humans, primarily children and young adults, and which enters the respiratory tract via airborne droplet and spreads to the lymphatic system.

The second component of this combination vaccine addresses an acute infectious disease caused by rubulavirus (a genus of the family paramyxoviridae and subfamily paramyxovirinae, where all the species have hemagglutinin and neuraminidase activities but lack a C protein), which is spread by direct contact, airborne droplet nuclei, fomites contaminated by infectious saliva, and perhaps urine, and usually seen in children under the age of 15, although adults may also be affected.

UNSPSC 51201648 Rubella and mumps virus vaccine is a Commodity code that state and local health departments use to procure immunization products. The recent activity under this code reflects state procurement of vaccines for public health programs, though the available opportunity record shows a sole source notice for Yellow Fever Vaccine rather than rubella and mumps products specifically, indicating possible coding variance in state procurement filings. State health departments appear to be the primary issuing bodies under this code, procuring vaccines to support immunization mandates and public health initiatives at the state level.

The Mississippi State Department of Health posted a sole source procurement notice (Solicitation Number 3150006922) on July 13, 2026, with objections due August 3, 2026, for Yellow Fever Vaccine from Sanofi Pasteur, Inc. The solicitation did not specify quantity, contract term, estimated value, or pricing. Mississippi appears in the recent record as a state-level buyer; geographic spread beyond Mississippi is not supported by available opportunity data. Vendors interested in state health department vaccine contracts should monitor sole source notices and objection windows closely, as states may pursue single-source awards when they determine exclusive supplier status, subject to public challenge and appeal to state procurement review boards.